Systematic surveillance of immune-related adverse events in clinical practice and impact of subsequent steroid medication on survival outcomes

Background Recent advances in immune-checkpoint inhibitors (ICIs) have highlighted the need for effective management of immune-related adverse events (irAEs). This study aimed to conduct a systematic surveillance of real-world development of irAEs for understanding their characteristics and examine...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical oncology 2023-07, Vol.28 (7), p.860-871
Main Authors: Matsukane, Ryosuke, Suetsugu, Kimitaka, Hata, Kojiro, Matsuda, Keisuke, Nakao, Satoshi, Minami, Haruna, Watanabe, Hiroyuki, Hirota, Takeshi, Egashira, Nobuaki, Ieiri, Ichiro
Format: Article
Language:English
Subjects:
Adverse events
Cancer Research
Hepatitis
Immune checkpoint inhibitors
Medical prognosis
Medicine
Medicine & Public Health
Methylprednisolone
Multivariate analysis
Oncology
Original Article
Patients
Pembrolizumab
Pneumonitis
Prognosis
Steroid hormones
Steroids
Surgical Oncology
Surveillance
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Recent advances in immune-checkpoint inhibitors (ICIs) have highlighted the need for effective management of immune-related adverse events (irAEs). This study aimed to conduct a systematic surveillance of real-world development of irAEs for understanding their characteristics and examine the prognostic impact of steroid use for these events. Methods We retrospectively investigated cancer patients treated with ICIs between 2014 and 2021 and collected information about irAEs throughout their development, management, and clinical outcomes. Results Overall, 458 patients (45.4%) developed 670 irAEs. The prevalence of irAEs varied by cancer type, but it was increased in regimens with longer treatment durations. Severe irAEs were more common in the nivolumab + ipilimumab and pembrolizumab + axitinib regimens. Patients who received steroids for irAEs at a dosage of 
ISSN:1341-9625
1437-7772
DOI:10.1007/s10147-023-02349-3